Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) – Research analysts at Oppenheimer Holdings decreased their Q3 2017 earnings per share (EPS) estimates for shares of Zynerba Pharmaceuticals in a report issued on Monday. Oppenheimer Holdings analyst D. Archila now expects that the company will post earnings of ($0.62) per share for the quarter, down from their previous estimate of ($0.59). Oppenheimer Holdings currently has a “Buy” rating and a $8.00 price target on the stock. Oppenheimer Holdings also issued estimates for Zynerba Pharmaceuticals’ Q4 2017 earnings at ($0.45) EPS, FY2017 earnings at ($2.31) EPS, FY2018 earnings at ($1.96) EPS, FY2019 earnings at ($2.18) EPS, FY2020 earnings at ($2.92) EPS and FY2021 earnings at ($2.47) EPS.

A number of other equities analysts have also recently issued reports on the company. Zacks Investment Research raised Zynerba Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, July 13th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $32.00 target price on shares of Zynerba Pharmaceuticals in a report on Sunday, July 9th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $28.00 target price on shares of Zynerba Pharmaceuticals in a report on Tuesday, May 9th. BidaskClub raised Zynerba Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, July 12th. Finally, Maxim Group set a $32.00 target price on Zynerba Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, June 26th. Two analysts have rated the stock with a sell rating, five have given a hold rating and four have given a buy rating to the company. Zynerba Pharmaceuticals presently has an average rating of “Hold” and an average target price of $17.89.

ILLEGAL ACTIVITY WARNING: “Q3 2017 EPS Estimates for Zynerba Pharmaceuticals, Inc. Cut by Analyst (ZYNE)” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another website, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/08/10/q3-2017-eps-estimates-for-zynerba-pharmaceuticals-inc-cut-by-analyst-zyne.html.

Shares of Zynerba Pharmaceuticals (ZYNE) opened at 7.60 on Wednesday. Zynerba Pharmaceuticals has a 52 week low of $6.20 and a 52 week high of $25.95. The stock has a 50 day moving average price of $17.54 and a 200-day moving average price of $19.50. The firm’s market capitalization is $100.75 million. Zynerba Pharmaceuticals also was the target of unusually large options trading on Monday. Stock investors purchased 7,953 put options on the company. This is an increase of approximately 726% compared to the average daily volume of 963 put options.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) last announced its earnings results on Tuesday, August 1st. The company reported ($0.64) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.60) by $0.04.

In related news, CFO James E. Fickenscher purchased 5,200 shares of Zynerba Pharmaceuticals stock in a transaction on Friday, May 12th. The shares were purchased at an average price of $19.82 per share, for a total transaction of $103,064.00. Following the transaction, the chief financial officer now owns 12,200 shares of the company’s stock, valued at approximately $241,804. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Chairman Armando Anido purchased 5,000 shares of Zynerba Pharmaceuticals stock in a transaction on Monday, May 15th. The stock was bought at an average price of $19.70 per share, for a total transaction of $98,500.00. Following the transaction, the chairman now directly owns 336,012 shares in the company, valued at approximately $6,619,436.40. The disclosure for this purchase can be found here. 10.02% of the stock is owned by corporate insiders.

Several large investors have recently added to or reduced their stakes in ZYNE. FNY Managed Accounts LLC bought a new stake in Zynerba Pharmaceuticals during the first quarter worth approximately $180,000. SG Americas Securities LLC bought a new stake in Zynerba Pharmaceuticals during the first quarter worth approximately $188,000. Rhumbline Advisers bought a new stake in Zynerba Pharmaceuticals during the second quarter worth approximately $232,000. Bank of New York Mellon Corp raised its stake in Zynerba Pharmaceuticals by 5.5% in the first quarter. Bank of New York Mellon Corp now owns 12,165 shares of the company’s stock worth $245,000 after buying an additional 635 shares during the period. Finally, Segantii Capital Management Ltd bought a new stake in Zynerba Pharmaceuticals during the first quarter worth approximately $291,000. Hedge funds and other institutional investors own 31.08% of the company’s stock.

Zynerba Pharmaceuticals Company Profile

Zynerba Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system.

Earnings History and Estimates for Zynerba Pharmaceuticals (NASDAQ:ZYNE)

Receive News & Stock Ratings for Zynerba Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.